Acute Myeloid Leukemia Treatment Market Size, Share and Growth Forecast for 2025 - 2032

Table of Content

1. Executive Summary
   1. Global Acute Myeloid Leukemia Treatment Market Snapshot, 2025 and 2032
   2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
   3. Key Market Trends
   4. Future Market Projections
   5. Premium Market Insights
   6. Industry Developments and Key Market Events
   7. PMR Analysis and Recommendations
2. Market Overview
   1. Market Scope and Definition
   2. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunity
      4. Challenges
      5. Key Trends
   3. Macro-Economic Factors
      1. Global Sectorial Outlook
      2. Global GDP Growth Outlook
   4. COVID-19 Impact Analysis
   5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   1. Regulatory Landscape
   2. Product Adoption Analysis
   3. Value Chain Analysis
   4. Key Deals and Mergers
   5. PESTLE Analysis
   6. Porter’s Five Force Analysis
4. Global Acute Myeloid Leukemia Treatment Market Outlook:
   1. Key Highlights
      1. Market Size (US$ Bn) and Y-o-Y Growth
      2. Absolute $ Opportunity
   2. Market Size (US$ Bn) Analysis and Forecast
      1. Historical Market Size (US$ Bn) Analysis, 2019-2024
      2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
   3. Global Acute Myeloid Leukemia Treatment Market Outlook: Treatment
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2019 - 2024
      3. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
         1. Chemotherapy
            1. Antimetabolites
            2. Hypomethylating Agents (HMAs)
            3. Antimetabolites
            4. Anthracyclines
            5. Alkylating Agents
            6. Others
         2. Targeted Therapy
            1. FLT3 Inhibitors
            2. BCL-2 Inhibitors
            3. IDH Inhibitors
            4. Others
         3. Immunotherapy
            1. Monoclonal Antibodies
            2. Immune Checkpoint Inhibitors
            3. Others
         4. Others
      4. Market Attractiveness Analysis: Treatment
   4. Global Acute Myeloid Leukemia Treatment Market Outlook: Disease
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Disease, 2019 - 2024
      3. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
         1. Myeloblastic Leukemia
         2. Myelomonocytic
         3. Leukemia
         4. Promyelocytic Leukemia
         5. Others
      4. Market Attractiveness Analysis: Disease
   5. Global Acute Myeloid Leukemia Treatment Market Outlook: Route of Administration
      1. Introduction / Key Findings
      2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019 - 2024
      3. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
         1. Parenteral
         2. Oral
      4. Market Attractiveness Analysis: Route of Administration
5. Global Acute Myeloid Leukemia Treatment Market Outlook: Region
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
   3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
      1. North America
      2. Europe
      3. East Asia
      4. South Asia and Oceania
      5. Latin America
      6. Middle East & Africa
   4. Market Attractiveness Analysis: Region
6. North America Acute Myeloid Leukemia Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Treatment
      3. By Disease
      4. By Route of Administration
   3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. U.S.
      2. Canada
   4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
      1. Chemotherapy
         1. Antimetabolites
         2. Hypomethylating Agents (HMAs)
         3. Antimetabolites
         4. Anthracyclines
         5. Alkylating Agents
         6. Others
      2. Targeted Therapy
         1. FLT3 Inhibitors
         2. BCL-2 Inhibitors
         3. IDH Inhibitors
         4. Others
      3. Immunotherapy
         1. Monoclonal Antibodies
         2. Immune Checkpoint Inhibitors
         3. Others
      4. Others
   5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
      1. Myeloblastic Leukemia
      2. Myelomonocytic
      3. Leukemia
      4. Promyelocytic Leukemia
      5. Others
   6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Parenteral
      2. Oral
   7. Market Attractiveness Analysis
7. Europe Acute Myeloid Leukemia Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Treatment
      3. By Disease
      4. By Route of Administration
   3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. Germany
      2. France
      3. U.K.
      4. Italy
      5. Spain
      6. Russia
      7. Türkiye
      8. Rest of Europe
   4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
      1. Chemotherapy
         1. Antimetabolites
         2. Hypomethylating Agents (HMAs)
         3. Antimetabolites
         4. Anthracyclines
         5. Alkylating Agents
         6. Others
      2. Targeted Therapy
         1. FLT3 Inhibitors
         2. BCL-2 Inhibitors
         3. IDH Inhibitors
         4. Others
      3. Immunotherapy
         1. Monoclonal Antibodies
         2. Immune Checkpoint Inhibitors
         3. Others
      4. Others
   5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
      1. Myeloblastic Leukemia
      2. Myelomonocytic
      3. Leukemia
      4. Promyelocytic Leukemia
      5. Others
   6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Parenteral
      2. Oral
   7. Market Attractiveness Analysis
8. East Asia Acute Myeloid Leukemia Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Treatment
      3. By Disease
      4. By Route of Administration
   3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. China
      2. Japan
      3. South Korea
   4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
      1. Chemotherapy
         1. Antimetabolites
         2. Hypomethylating Agents (HMAs)
         3. Antimetabolites
         4. Anthracyclines
         5. Alkylating Agents
         6. Others
      2. Targeted Therapy
         1. FLT3 Inhibitors
         2. BCL-2 Inhibitors
         3. IDH Inhibitors
         4. Others
      3. Immunotherapy
         1. Monoclonal Antibodies
         2. Immune Checkpoint Inhibitors
         3. Others
      4. Others
   5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
      1. Myeloblastic Leukemia
      2. Myelomonocytic
      3. Leukemia
      4. Promyelocytic Leukemia
      5. Others
   6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Parenteral
      2. Oral
   7. Market Attractiveness Analysis
9. South Asia & Oceania Acute Myeloid Leukemia Treatment Market Outlook:
   1. Key Highlights
   2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
      1. By Country
      2. By Treatment
      3. By Disease
      4. By Route of Administration
   3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
      1. India
      2. Southeast Asia
      3. ANZ
      4. Rest of South Asia & Oceania
   4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
      1. Chemotherapy
         1. Antimetabolites
         2. Hypomethylating Agents (HMAs)
         3. Antimetabolites
         4. Anthracyclines
         5. Alkylating Agents
         6. Others
      2. Targeted Therapy
         1. FLT3 Inhibitors
         2. BCL-2 Inhibitors
         3. IDH Inhibitors
         4. Others
      3. Immunotherapy
         1. Monoclonal Antibodies
         2. Immune Checkpoint Inhibitors
         3. Others
      4. Others
   5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
      1. Myeloblastic Leukemia
      2. Myelomonocytic
      3. Leukemia
      4. Promyelocytic Leukemia
      5. Others
   6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
      1. Parenteral
      2. Oral
   7. Market Attractiveness Analysis
10. Latin America Acute Myeloid Leukemia Treatment Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Treatment
       3. By Disease
       4. By Route of Administration
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. Brazil
       2. Mexico
       3. Rest of Latin America
    4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
       1. Chemotherapy
          1. Antimetabolites
          2. Hypomethylating Agents (HMAs)
          3. Antimetabolites
          4. Anthracyclines
          5. Alkylating Agents
          6. Others
       2. Targeted Therapy
          1. FLT3 Inhibitors
          2. BCL-2 Inhibitors
          3. IDH Inhibitors
          4. Others
       3. Immunotherapy
          1. Monoclonal Antibodies
          2. Immune Checkpoint Inhibitors
          3. Others
       4. Others
    5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
       1. Myeloblastic Leukemia
       2. Myelomonocytic
       3. Leukemia
       4. Promyelocytic Leukemia
       5. Others
    6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
       1. Parenteral
       2. Oral
    7. Market Attractiveness Analysis
11. Middle East & Africa Acute Myeloid Leukemia Treatment Market Outlook:
    1. Key Highlights
    2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
       1. By Country
       2. By Treatment
       3. By Disease
       4. By Route of Administration
    3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
       1. GCC Countries
       2. Egypt
       3. South Africa
       4. Northern Africa
       5. Rest of Middle East & Africa
    4. Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2025 - 2032
       1. Chemotherapy
          1. Antimetabolites
          2. Hypomethylating Agents (HMAs)
          3. Antimetabolites
          4. Anthracyclines
          5. Alkylating Agents
          6. Others
       2. Targeted Therapy
          1. FLT3 Inhibitors
          2. BCL-2 Inhibitors
          3. IDH Inhibitors
          4. Others
       3. Immunotherapy
          1. Monoclonal Antibodies
          2. Immune Checkpoint Inhibitors
          3. Others
       4. Others
    5. Market Size (US$ Bn) Analysis and Forecast, By Disease, 2025 - 2032
       1. Myeloblastic Leukemia
       2. Myelomonocytic
       3. Leukemia
       4. Promyelocytic Leukemia
       5. Others
    6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
       1. Parenteral
       2. Oral
    7. Market Attractiveness Analysis
12. Competition Landscape
    1. Market Share Analysis, 2024
    2. Market Structure
       1. Competition Intensity Mapping By Market
       2. Competition Dashboard
    3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       1. Astellas Pharma Inc.
          1. Overview
          2. Segments and Products
          3. Key Financials
          4. Market Developments
          5. Market Strategy
       2. Bristol Myers Squibb Company
       3. Daiichi Sankyo Company, Limited
       4. Jazz Pharmaceuticals, plc
       5. Novartis AG
       6. Pfizer, Inc.
       7. Rigel Pharmaceuticals, Inc.
       8. AbbVie Inc.
       9. Servier Laboratories
13. Appendix
    1. Research Methodology
    2. Research Assumptions
    3. Acronyms and Abbreviations